FDA Sets PDUFA Date for Investigational Glaucoma Eye Drop
The FDA accepts Nicox’s NDA for an investigational glaucoma drop; Bausch + Lomb provides updates on two key investigational therapies for dry eye and ocular surface pain; and Ocugen doses the first patient in a global phase 3 trial of an investigational gene therapy for geographic atrophy (GA). Learn more about your ad choices. Visit megaphone.fm/adchoices
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Eyewire News: The Podcast
Breaking News From the ESCRS Congress in London (Part 1 of 2)
FDA Accepts Nanoscopes's Optogenetic Gene Therapy BLA
EyePoint Misses Primary Endpoint in Phase 3 Trial But Sees Promise After Analysis
Three Major Acquisitions Announced in Ophthalmology
Get summaries like this every morning.
Free AI-powered recaps of Eyewire News: The Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.